GlassScriptPhysician profile
Sergiu L Marcus
NPI 1922087766
$8,701.86
in general payments reported to CMS, 2019-2025
20 companies · $1,441 in 2025
The $1,441 reported for 2025 was more than what 84% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $352 · 2020: $563 · 2021: $1,383 · 2022: $1,604 · 2023: $1,688 · 2024: $1,673 · 2025: $1,441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,711 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,711.18 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,746.71 | 2019-2025 | Eylea Hd, Eylea |
| Mallinckrodt Hospital Products INC. | $1,099.92 | 2020-2024 | Acthar |
| Alimera Sciences, INC. | $994.75 | 2020-2024 | Iluvien, Yutiq |
| Abbvie INC. | $904.01 | 2022-2025 | |
| Astellas Pharma US INC | $819.09 | 2023-2025 | Izervay |
| Genentech USA, INC. | $768.00 | 2021-2025 | Vabysmo, Susvimo |
| Harrow Eye, LLC | $479.07 | 2024-2025 | Iheezo, Triesence |
| Allergan, INC. | $407.82 | 2019-2021 | |
| Eyepoint US, INC. | $353.07 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $319.51 | 2019-2022 | |
| Coherus Oncology, INC. | $161.49 | 2023 | |
| Sandoz INC. | $160.28 | 2024 | Cimerli |
| Biotissue Holdings INC. | $155.69 | 2022-2024 | |
| Apellis Pharmaceuticals, INC. | $97.77 | 2022-2025 | Syfovre |
| Ani Pharmaceuticals, INC. | $77.22 | 2025 | Purified Cortrophin Gel, Iluvien |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $49.49 | 2019 | |
| Bausch & Lomb Americas INC. | $40.81 | 2024-2025 | Xipere |
| Biogen, INC. | $32.42 | 2022-2023 | |
| Sun Pharmaceutical Industries INC. | $18.45 | 2025 | |
| Glaukos Corporation | $16.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sergiu Marcus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.